Roche to Acquire LumiraDx Point-of-Care Technology Platform for $295 Million
January 2, 2024
LumiraDx has entered into a definitive agreement for Roche to acquire certain companies and related assets within LumiraDx’s point-of-care diagnostics platform business. Roche will pay $295 million at closing, with an additional payment of up to $55 million for reimbursement to fund the platform business until closing.
- Buyers
- Roche
- Targets
- LumiraDx Group Limited, LumiraDx International Limited
- Sellers
- Andrew Johnson, Lisa Rickelton, Lindsay Hallam (FTI Consulting LLP) as joint administrators of LumiraDx subsidiaries
- Industry
- Healthcare Services
- Location
- United Kingdom
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
QuidelOrtho Acquires LEX Diagnostics to Expand Ultra-Fast Point-of-Care PCR
April 20, 2026
Healthcare Services
QuidelOrtho Corporation completed the acquisition of LEX Diagnostics for approximately $100 million in cash. The deal adds the LEX VELO System, an ultra-fast molecular (multiplex RT-PCR) platform designed to deliver results for Influenza A, Influenza B, and COVID-19 in about six to ten minutes from a swab.
-
Roche to Acquire 89bio for Up to $3.5 Billion
September 22, 2025
Pharmaceuticals
Roche has reached an agreement to acquire 89bio, a biopharmaceutical company focused on treatments for liver diseases and cardiometabolic conditions. The deal is expected to close in the fourth quarter of 2025, with an offered price of $14.50 per share in cash plus potential contingent value rights tied to performance milestones for pegozafermin.
-
Roche Acquires Poseida Therapeutics
November 28, 2024
Biotechnology
Roche Holdings, Inc. has agreed to acquire San Diego-based Poseida Therapeutics for $9.00 per share in cash plus a contingent value right (CVR) for up to $4.00 per share, representing an aggregate equity value of up to $1.5 billion. The acquisition will bring Poseida's non-viral gene-editing platforms, allogeneic TSCM-rich CAR-T programs and in-house GMP cell therapy manufacturing into Roche's Pharmaceuticals Division to establish a new core capability in allogeneic cell therapy.
-
Caldera Medical Acquires UVision 360 and the LUMINELLE Product Family
October 8, 2024
Medical Devices
Caldera Medical has acquired UVision 360, the developer of the LUMINELLE hysteroscopy and cystoscopy systems, expanding its minimally invasive women's health device portfolio. The deal brings the LUMINELLE product family — including the new LUMINELLE Bx on-demand biopsy technology — into Caldera's commercial infrastructure to broaden office-based and surgical hysteroscopy capabilities.
-
LumiThera Acquires Diopsys
November 11, 2021
Medical Devices
LumiThera, a commercial-stage ophthalmic medical device company, entered a definitive merger agreement to acquire Diopsys in a stock-for-stock transaction under which Diopsys will become a wholly owned subsidiary of LumiThera. The deal combines Diopsys' visual electrophysiology diagnostic systems with LumiThera's photobiomodulation treatment platform to create a coordinated light-based theranostic approach for diagnosing, treating and monitoring ocular disease.
-
DiscernDx Acquires Luminist Labs
April 29, 2020
Biotechnology
DiscernDx, a Palo Alto precision medicine company, has acquired Luminist Labs, a privately-held diagnostic platform developer focused on early detection and diagnosis of liver disease. The acquisition will integrate Luminist's data and platform into DiscernDx's multi-omics system to accelerate development of non-invasive diagnostic and prognostic solutions for NASH and other chronic metabolic liver diseases. Terms were not disclosed.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.